Cambridge Investment Research Advisors
VBIV

Cambridge Investment Research Advisors’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-67,113
Closed -$44K – 3548
2024
Q2 		$44K Sell
67,113
-16,969
-20% -$10.6K ﹤0.01% 3230
2024
Q1 		$51K Sell
84,082
-4,312
-5% -$2.64K ﹤0.01% 3212
2023
Q4 		$52K Sell
88,394
-5,162
-6% -$3.11K ﹤0.01% 3097
2023
Q3 		$62K Sell
93,556
-6,812
-7% -$8.35K ﹤0.01% 3019
2023
Q2 		$330K Sell
100,368
-7,035
-7% -$21.3K ﹤0.01% 2460
2023
Q1 		$976K Sell
107,403
-3,491
-3% -$49.5K ﹤0.01% 1593
2022
Q4 		$1.3M Buy
110,894
+6,476
+6% +$114K 0.01% 1341
2022
Q3 		$2.21M Buy
104,418
+29,980
+40% +$808K 0.01% 975
2022
Q2 		$1.81M Buy
74,438
+1,448
+2% +$49.3K 0.01% 1096
2022
Q1 		$3.63M Buy
72,990
+1,440
+2% +$71.2K 0.02% 802
2021
Q4 		$5.02M Buy
71,550
+2,685
+4% +$226K 0.02% 643
2021
Q3 		$6.42M Buy
68,865
+4,039
+6% +$384K 0.03% 505
2021
Q2 		$6.51M Buy
64,826
+5,831
+10% +$568K 0.03% 511
2021
Q1 		$5.5M Buy
58,995
+4,161
+8% +$422K 0.03% 526
2020
Q4 		$4.52M Sell
54,834
-6,344
-10% -$541K 0.03% 563
2020
Q3 		$5.25M Buy
61,178
+4,020
+7% +$468K 0.04% 447
2020
Q2 		$5.32M Buy
57,158
+172
+0.3% +$9.48K 0.04% 420
2020
Q1 		$1.62M Sell
56,986
-217
-0.4% -$8.44K 0.02% 752
2019
Q4 		$2.37M Buy
57,203
+3,031
+6% +$66.4K 0.02% 721
2019
Q3 		$766K Buy
54,172
+6,254
+13% +$131K 0.01% 1237
2019
Q2 		$1.68M Buy
47,918
+3,097
+7% +$168K 0.02% 788
2019
Q1 		$2.51M Sell
44,821
-16
-0% -$865 0.02% 627
2018
Q4 		$2.15M Sell
44,837
-764
-2% -$41.9K 0.02% 610
2018
Q3 		$3.31M Buy
45,601
+2,219
+5% +$146K 0.03% 493
2018
Q2 		$3.58M Sell
43,382
-2,999
-6% -$290K 0.04% 436
2018
Q1 		$4.87M Sell
46,381
-1,036
-2% -$124K 0.05% 325
2017
Q4 		$6.07M Buy
47,417
+229
+0.5% +$28.2K 0.07% 268
2017
Q3 		$5.45M Buy
47,188
+1,255
+3% +$151K 0.07% 263
2017
Q2 		$5.99M Buy
45,933
+5
+0% +$675 0.09% 214
2017
Q1 		$7.56M Sell
45,928
-218
-0.5% -$29.5K 0.13% 144
2016
Q4 		$4.29M Buy
46,146
+201
+0.4% +$19.2K 0.08% 234
2016
Q3 		$4.73M Buy
45,945
+11,255
+32% +$1.26M 0.09% 216
2016
Q2 		$4.11M Sell
34,690
-23,409
-40% -$2.35M 0.09% 216
2016
Q1 		$4.1M Buy
58,099
+10,329
+22% +$683K 0.09% 203
2015
Q4 		$3.5M Buy
+47,770
New +$3.65M 0.08% 239

Cambridge Investment Research Advisors's VBIV Position: Q3 2024 in Review

Cambridge Investment Research Advisors sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 67,113 shares — an estimated $44K sold.

Cambridge Investment Research Advisors first reported a position in VBIV in Q4 2015 and held it in 35 quarters. The position peaked at $7.56M in Q1 2017. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

  • Cambridge Investment Research Advisors reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 67,113 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $44K.
  • Cambridge Investment Research Advisors first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2015 and held it in 35 quarters.
  • Cambridge Investment Research Advisors's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $7.56M in Q1 2017.
  • 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2024, filed 28 Oct 2024.